May 2026, Vol 16, No 3

Self-insured employers are understandably concerned about the costs of pharmacy benefits for their employees. Read More ›

For so many people, healthcare doesn’t begin in an exam room—it begins with anxiety. Read More ›

The financial aspect of cancer care deeply affects the patient’s experience economically, physically, and psychologically. Read More ›

This study investigates the implementation of social risk factor screening and referral processes in cancer survivorship care within 3 oncology settings in Washington, DC. Read More ›

On February 24, 2026, the FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adults with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, as determined by an FDA-authorized test. Read More ›

On February 19, 2026, the FDA approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read More ›

On March 5, 2026, the FDA approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Read More ›

On February 26, 2026, the FDA granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)-activating mutations. Read More ›

On March 11, 2026, the FDA announced the launch of the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to modernize and streamline the agency’s analysis of adverse event reports. Read More ›